<?xml-model href='http://www.tei-c.org/release/xml/tei/custom/schema/relaxng/tei_all.rng' schematypens='http://relaxng.org/ns/structure/1.0'?><TEI xmlns="http://www.tei-c.org/ns/1.0">
	<teiHeader>
		<fileDesc>
			<titleStmt><title level='a'>The Role of the Rhomboid Superfamily in ER Protein Quality Control: From Mechanisms and Functions to Diseases</title></titleStmt>
			<publicationStmt>
				<publisher>Cold Spring Harbor</publisher>
				<date>02/01/2023</date>
			</publicationStmt>
			<sourceDesc>
				<bibl> 
					<idno type="par_id">10497434</idno>
					<idno type="doi">10.1101/cshperspect.a041248</idno>
					<title level='j'>Cold Spring Harbor Perspectives in Biology</title>
<idno>1943-0264</idno>
<biblScope unit="volume">15</biblScope>
<biblScope unit="issue">2</biblScope>					

					<author>Satarupa Bhaduri</author><author>Nicola A. Scott</author><author>Sonya E. Neal</author>
				</bibl>
			</sourceDesc>
		</fileDesc>
		<profileDesc>
			<abstract><ab><![CDATA[The ubiquitin proteasome system maintains protein homeostasis by regulating the breakdown of misfolded proteins, thereby preventing misfolded protein aggregates. The efficient elimination is vital for preventing damage to the cell by misfolded proteins, known as proteotoxic stress. Proteotoxic stress can lead to the collapse of protein homeostasis and can alter the function of the ubiquitin proteasome system. Conversely, impairment of the ubiquitin proteasome system can also cause proteotoxic stress and disrupt protein homeostasis. This review examines two impacts of proteotoxic stress, 1) disruptions to ubiquitin homeostasis (ubiquitin stress) and 2) disruptions to proteasome homeostasis (proteasome stress). Here, we provide a mechanistic description of the relationship between proteotoxic stress and the ubiquitin proteasome system. This relationship is illustrated by findings from several protein misfolding diseases, mainly neurodegenerative diseases, as well as from basic biology discoveries from yeast to mammals. In addition, we explore the importance of the ubiquitin proteasome system in endoplasmic reticulum quality control, and how proteotoxic stress at this organelle is alleviated. Finally, we highlight how cells utilize the ubiquitin proteasome system to adapt to proteotoxic stress and how the ubiquitin proteasome system can be genetically and pharmacologically manipulated to maintain protein homeostasis.]]></ab></abstract>
		</profileDesc>
	</teiHeader>
	<text><body xmlns="http://www.tei-c.org/ns/1.0" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink">
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="1.">Introduction</head><p>Proper protein function is crucial for maintaining normal cellular processes and health. For those functions to be carried out, proteins must be folded into their proper, native confirmations. Many challenges and disruptions, such as gene mutations, errors in protein translation, oxidative damage, and toxic environmental conditions, can occur during the process of protein folding <ref type="bibr">[1]</ref><ref type="bibr">[2]</ref><ref type="bibr">[3]</ref><ref type="bibr">[4]</ref><ref type="bibr">[5]</ref><ref type="bibr">[6]</ref>. These disruptions result in protein misfolding or non-native protein conformations. Because protein misfolding is a common occurrence in cells, cells have sophisticated mechanisms for recognizing and removing misfolded proteins. However, when these mechanisms fail, misfolded proteins accumulate, leading to proteotoxicity or cellular damage <ref type="bibr">[7]</ref>.</p><p>The abundance of specific proteins is a tightly controlled process in eukaryotic cells, with protein quality control (PQC) pathways employed to maintain protein homeostasis (proteostasis). The ubiquitin proteasome system (UPS) is the primary route by which proteins are degraded in eukaryotic cells <ref type="bibr">[8]</ref>. The UPS is widely used to maintain cellular homeostasis by removing misfolded or damaged proteins, as well as controlling the levels of specific regulatory proteins <ref type="bibr">[9]</ref><ref type="bibr">[10]</ref><ref type="bibr">[11]</ref>. The UPS is also utilized to remove unassembled subunits of larger protein complexes and to regulate the activity of cellular pathways by degrading proteins in the pathway, thus modulating pathway output. <ref type="bibr">[12,</ref><ref type="bibr">13]</ref>. In this pathway, a small polypeptide, ubiquitin (Ub), is post-translationally conjugated to a target protein. Ub marks the protein for disposal by a large protein complex, the proteasome, which recognizes and proteolytically degrades target proteins (Table <ref type="table">1</ref>).</p><p>While proteotoxic stress can impact cells through a variety of mechanisms, a common mechanism is by causing dysfunction to the UPS. In turn, UPS impairment, either by pharmacological means, genetic alterations, or non-proteotoxic stressors, can also disrupt proteostasis. A properly functioning UPS is also critical in preventing and adapting to proteotoxic stress. If the UPS fails to prevent proteotoxic stress, cells are equipped with pathways that activate transcriptional programs which aim to restore proteostasis, including the unfolded protein response as well as the proteasome stress response in yeast and the proteasome recovery pathway in mammals. This review will explore proteotoxic stress as a cause of UPS dysfunction, primarily focusing on ubiquitin and proteasome stress, and the ability of the UPS to ameliorate proteotoxicity, with a focus on cell culture, mice, and yeast. The final section of this review will also focus specifically on quality control at the endoplasmic reticulum and the impacts of proteotoxic stress from this organelle. The review will also merge basic biology discoveries on PQC with our understanding of diseases where the UPS is affected.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="1.1.">Misfolded protein structures</head><p>Protein misfolding refers to a single protein that is not properly folded. Many times, misfolded proteins form larger structures of multiple interacting misfolded proteins, known as protein aggregates. Protein aggregation is often driven by exposed hydrophobic regions of proteins and high concentrations of aggregation-prone proteins can increase the likelihood of protein aggregation <ref type="bibr">[14]</ref><ref type="bibr">[15]</ref><ref type="bibr">[16]</ref>. While hydrophobic stretches in proteins can increase the likelihood that a protein aggregates, there are no strict sequence requirements for protein aggregation <ref type="bibr">[17,</ref><ref type="bibr">18]</ref>. Protein aggregation encompasses a wide variety of non-native multi-protein interactions and is examined in more detail in the review by <ref type="bibr">Mogk,</ref><ref type="bibr">A.,</ref><ref type="bibr">et al. [19]</ref>.</p><p>Collectively, deleterious cellular effects caused by aggregated and misfolded proteins are referred to as proteotoxic stress. While some aggregates can be toxic and are implicated in the pathogenesis of many diseases, other aggregates are tolerated by cells or even serve adaptive purposes, such as transient aggregates that form under heat stress which protect the proteome <ref type="bibr">[20,</ref><ref type="bibr">21]</ref>. Two mechanisms of toxicity by protein aggregates are 1) sequestration and subsequent inactivation of proteins by large aggregates and 2) inhibition of proteins by direct binding of small aggregates <ref type="bibr">[22,</ref><ref type="bibr">23]</ref>. It has been appreciated for over two decades that misfolded protein aggregation can impair the UPS <ref type="bibr">[24]</ref>.</p><p>Protein aggregates can form various structures, such as soluble oligomers, amyloid fibrils, and amorphous aggregates (Fig. <ref type="figure">2</ref>). While amyloid fibrils are a general histological indicator of neurodegenerative disease, existing evidence points toward soluble oligomer aggregates as a common driver of cytotoxicity <ref type="bibr">[24,</ref><ref type="bibr">25]</ref>. Amorphous aggregates, such as inclusion bodies (IBs), are also commonly found in neurons in patients with neurodegenerative diseases, and are an adaptation by cells to sequester toxic oligomers, known as cytoprotective protein aggregation <ref type="bibr">[26]</ref>. Ub is commonly found in IBs, but in most cases, IBs do not appear to be the cause of UPS dysfunction. UPS dysfunction is triggered before the formation of IBs, indicating IBs can be an adaptive response to proteasome impairment triggered by smaller, more cytotoxic aggregates <ref type="bibr">[27]</ref>. Insoluble protein aggregates, like IBs, are generally resistant to proteasomal degradation and are instead disposed of by autophagy, another PQC pathway <ref type="bibr">[28]</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="1.2.">Protein misfolding diseases and the UPS</head><p>Diseases that are driven by misfolded and aggregated proteins are known as protein misfolding diseases <ref type="bibr">[2]</ref>. Some of these diseases, like cystic fibrosis, are loss of function diseases driven by specific protein mutations that cause misfolding and target the protein for degradation <ref type="bibr">[29,</ref><ref type="bibr">30]</ref>. Other protein misfolding diseases, most notably many neurodegenerative diseases, result in amyloids of specific proteins, but are not usually caused by mutations in the aggregated protein. This latter category of protein misfolding diseases has a variety of genetic risk factors associated with each disease <ref type="bibr">[31,</ref><ref type="bibr">32]</ref>. Protein aggregation is a common theme among neurodegenerative diseases and is a well-studied context in which proteotoxic stress and its impact on the UPS has been researched (Table <ref type="table">1</ref>). As such, much of the research reviewed here will be in relation to neurodegeneration (highlighted in Section 2.1.1 Proteasome Stress in Neurodegeneration).</p><p>1.3. The ubiquitin proteasome system machinery 1.3.1. Ubiquitin-Ubiquitination is a post-translational modification commonly used to target proteins for degradation by the proteasome <ref type="bibr">[33]</ref>. Ub is a small (76 amino acid), tightly folded polypeptide that can be covalently attached to a target protein through an isopeptide bond, most frequently on lysine residues, and less frequently to cysteine, serine, and threonine residues <ref type="bibr">[34]</ref>. Ubiquitination as a post-translational modification can be used for targeting proteins for proteolytic degradation, as well as other signaling purposes, such as triggering a DNA damage repair <ref type="bibr">response, autophagy, and endocytosis [35]</ref>. This review will focus primarily on ubiquitination as a signal for degradation.</p><p>Proteins can either be monoubiquitinated or tagged with a chain of Ubs, called polyubiquitination. Monoubiquitination is most commonly used as signaling modification on proteins, most notably in regulating the DNA damage response <ref type="bibr">[36]</ref><ref type="bibr">[37]</ref><ref type="bibr">[38]</ref>. Generally, proteins targeted for degradation become polyubiquitinated, meaning subsequent Ubs are conjugated to the first Ub through the lysine residues of Ub. The polyubiquitin (polyUb) chains that target proteins to degradation are usually chains of at least four Ub proteins <ref type="bibr">[39]</ref>. Ub contains 7 lysine residues (K6, K11, K27, K29, K33, K48, and K63), and the C-terminal of one Ub can be conjugated to any of the lysine residues of another Ub. As an example of the nomenclature used to describe Ub linkages, a Ub chain where each Ub is attached through the K63 residue would be a K63 linkage and a chain where some Ubs are conjugated to K11 and some to K63 would be called a mixed linkage chain. Different lengths of Ub chains and different linkage types cause different cellular effects, known as the Ub code <ref type="bibr">[5]</ref>. For example, the K48 linkage is most commonly associated with protein degradation <ref type="bibr">[40]</ref>, although, in yeast, cytoplasmic UPS targets must have both K11 and K48 linkages to be degraded <ref type="bibr">[41]</ref>.</p><p>In addition to Ub, eukaryotic cells also utilize ubiquitin-like proteins (UBLs) <ref type="bibr">[42]</ref>. While there are many UBL families expressed in mammalian cells, this review will touch on the role of the UBL SUMO (small--ubiquitin-related modifier) in SUMOylation and NEDD8 in neddylation (Section 2.2.2 Friends of Ubiquitin: Ubiquitin-like proteins in Stress).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>1.3.2.</head><p>The ubiquitin symphony: E1s, E2s, E3s, and deubiquitinases in concerts-Essential players in the UPS are the enzymes in the conjugation cascade that enables Ub to be attached to target proteins, the enzymes responsible for removing Ub from proteins, and the enzymes that break down Ub chains <ref type="bibr">(Fig 1)</ref>. For Ub to be conjugated to a target protein, it must first go through a cascade of E1 ubiquitin-activating enzymes, E2 ubiquitin-conjugating enzymes, and E3 ubiquitin ligases. First, Ub is conjugated to an E1 ubiquitin-activating enzyme by a thioester bond on a cysteine residue in an ATP-dependent manner <ref type="bibr">[43,</ref><ref type="bibr">44]</ref>. Next, Ub is transferred to a cysteine residue on an E2 ubiquitin-conjugating enzyme <ref type="bibr">[45,</ref><ref type="bibr">46]</ref>. Finally, an E3 ubiquitin ligase binds the ubiquitinated E2 enzyme and the target protein to promote ubiquitination of the target protein <ref type="bibr">[47]</ref><ref type="bibr">[48]</ref><ref type="bibr">[49]</ref>. For some E3 ligases, Ub is first transferred to the E3 before being transferred to the target protein <ref type="bibr">[50]</ref>. Once an initial Ub is added to a target protein, the cycle can be repeated to conjugate additional Ubs to the first and create a polyUb chain.</p><p>In total, the human genome contains over 800 genes encoding UPS components, including hundreds of E1, E2, and E3 enzymes <ref type="bibr">[51]</ref>. The human genome encodes two E1 enzymes, about 40 E2 enzymes, and about 600 E3 ligases, giving layers of specificity to which target proteins are ubiquitinated by UPS machinery. UBLs also use their own set of E1, E2, and E3 enzymes, with some instances in which they are conjugated by ubiquitin-specific enzymes <ref type="bibr">[52]</ref>.</p><p>Just as E1s, E2s, and E3s are specialized for attaching ubiquitin to target proteins, deubiquitinases (DUBs) are proteases that specifically cleave the isopeptide bonds formed by Ub. Different DUBs have specificity for certain types of Ub linkages and have specific roles in Ub cleavage, such as removing entire polyUb chains or breaking down polyUb chains into monomeric Ubs <ref type="bibr">[53,</ref><ref type="bibr">54]</ref>. DUBs play important roles in recycling Ub, regulating Ub chain lengths, and modulating the rate of degradation of UPS targets <ref type="bibr">[55]</ref><ref type="bibr">[56]</ref><ref type="bibr">[57]</ref><ref type="bibr">[58]</ref><ref type="bibr">[59]</ref>.</p><p>1.3.3. The proteasome-The proteasome is a large protein complex found in both the cytoplasm and nucleus that degrades proteins <ref type="bibr">[60]</ref>. The 26 S proteasome, which is the proteasome configuration that degrades ubiquitinated proteins, consists of two major components, the 20 S core particle (proteolytic core) and the 19 S regulatory particle (proteasome cap), with a proteasome cap on either side of the core <ref type="bibr">[61]</ref><ref type="bibr">[62]</ref><ref type="bibr">[63]</ref><ref type="bibr">[64]</ref>.</p><p>The 20 S core forms a narrow cylinder (maximum of 53&#197;) and can only be entered by unfolded proteins <ref type="bibr">[65]</ref>. It is composed of 4 stacked rings, each made out of 7 distinct subunits <ref type="bibr">[61]</ref>. Of these 4 rings, the 2 inner rings are made of seven &#946; subunits, three of which have protease activity, while the two outer rings are made of &#593; subunits, which lack a proteolytic function <ref type="bibr">[61,</ref><ref type="bibr">66]</ref>. The 20 S core of the proteasome has trypsin-like, chymotrypsin-like, and caspase-like proteolytic activity, with each activity provided by a different proteolytic &#946; subunit <ref type="bibr">[67,</ref><ref type="bibr">68]</ref>. These various proteolytic functions allow the proteasome to progressively cleave most proteins into small peptide fragments in an ATPdependent manner, with the ATPase activity provided by the 19 S proteasome <ref type="bibr">[69]</ref>. To regulate protein degradation, the &#593; subunits composing the outer rings of the core form a gate channel with their N-terminals <ref type="bibr">[61,</ref><ref type="bibr">70]</ref>. The gating mechanism ensures that only unfolded proteins trigger conformational changes that allow substrates to enter the core.</p><p>The cap of the proteasome serves to recognize ubiquitinated substrates, remove Ub, unfold target proteins, and translocate unfolded proteins into the proteolytic core <ref type="bibr">[71]</ref><ref type="bibr">[72]</ref><ref type="bibr">[73]</ref>. The 19 S regulatory particle is composed of 19 subunits and two rings <ref type="bibr">[74]</ref>. The base (the portion that interacts with the 20 S core particle) is made of 6 distinct ATPase subunits and 3 non-ATPase subunits <ref type="bibr">[75]</ref>. Besides providing the energy for translocating unfolded proteins into the core, the ATPase units of the regulatory particle base, Rpt1-6 in yeast (Psmc2, Psmc1, Psmc4, Psmc6, Psmc3, and Psmc5 in humans, respectively), are also responsible for changing the conformation of the gate in the 20 S core to an open conformation <ref type="bibr">[76,</ref><ref type="bibr">77]</ref>. Two of the non-ATPase subunits of the base, Rpn1 and Rpn2 in yeast (Psmd2 and Psmd1 in humans, respectively), serve as binding sites for Ub while the third non-ATPase subunit, Rpn13 (Adrm1 in humans), is a Ub receptor <ref type="bibr">[75,</ref><ref type="bibr">78]</ref>. The top ring, or lid, is composed of 9 subunits, primarily structural proteins and one DUB, Rpn11 in yeast (Psmd14 in humans) <ref type="bibr">[79]</ref>. The final subunit of the regulatory particle, Rpn10 in yeast (Psmd4 in humans), essentially connects the lid and the base <ref type="bibr">[80,</ref><ref type="bibr">81]</ref>.</p><p>In addition to the subunits mentioned above, the regulatory particle also associates with additional DUBs, Usp14 (Ubp6 in yeast) and Uch37 in humans <ref type="bibr">[82]</ref><ref type="bibr">[83]</ref><ref type="bibr">[84]</ref><ref type="bibr">[85]</ref>. The role of proteasome-associated DUBs is critical for protein degradation by the proteasome, as the regulatory particle only allows ubiquitinated proteins to be translocated to the core particle, but Ub is not necessary after initially being recognized by Ub receptors in the regulatory particle <ref type="bibr">[86]</ref>. In fact, Ub remaining on proteasome targets during degradation can slow protein turnover, due to delayed unfolding of target proteins <ref type="bibr">[58]</ref>. DUBs allow Ub to be removed from proteins, so that the Ub does not get degraded with the rest of the protein, thus recycling Ub for continued use in the cell <ref type="bibr">[59,</ref><ref type="bibr">87,</ref><ref type="bibr">88]</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.">Proteotoxic stress impacting the ubiquitin proteasome system</head><p>Proteotoxic stress can impact the UPS directly, through the interaction of protein aggregates with UPS machinery, or as a downstream effect through non-direct mechanisms. In this section, we will examine the impacts of misfolded and aggregated proteins on both proteasome stress and ubiquitin stress (Fig. <ref type="figure">3</ref>) <ref type="bibr">[59]</ref>. For this review, we are defining proteasome stress as any reduction in proteasome activity that results in inefficient clearance of proteasome substrates. We are defining ubiquitin stress as a state where the amount of unconjugated Ub in the cell is altered to a level that normal cellular processes involving Ub are impacted. The terms proteasome stress and ubiquitin stress were coined by Daniel Finley's lab in an influential 2007 Cell paper [49].</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.1.">Proteasome stress</head><p>2.1.1. Proteasome stress in neurodegeneration-Alzheimer's disease (AD) is a neurodegenerative disorder in which patients present with extracellular protein deposits (aggregates) in the brain, followed by neuronal cell death. Amyloid &#946; (A&#946;) deposits are one of the hallmarks of AD and one of the common A&#946; isoforms, A&#946;42, is neurotoxic when in a soluble, oligomeric aggregated state (Table <ref type="table">1</ref>) <ref type="bibr">[89]</ref>. A&#946; is proteolytically derived from Amyloid Precursor Protein (APP), through consecutive processing by the proteases &#946;-secretase 1 followed by &#947;-secretase <ref type="bibr">[90]</ref>. The normal physiological function of APP is not completely understood, but existing evidence shows a role for APP and secreted A&#946; in normal neuronal processes, such as neuronal cell migration during development, synaptic function, and transcriptional regulation <ref type="bibr">[91]</ref><ref type="bibr">[92]</ref><ref type="bibr">[93]</ref>. A&#946;42 causes proteasome inhibition in vitro <ref type="bibr">[94]</ref>, and proteasome function is reduced in the brains of AD patients and in AD mouse models <ref type="bibr">[95,</ref><ref type="bibr">96]</ref>. Notably, the decrease in proteasome activity in humans and mice is not accompanied by a reduction in proteasome expression <ref type="bibr">[95,</ref><ref type="bibr">96]</ref>. A&#946;42 applied extracellularly to rat neuroblastoma cells (B103), cells that do not endogenously produce A&#946;42, results in proteasome impairment, as measured through a proteasome-targeted GFP reporter <ref type="bibr">[97]</ref>. Even when applied extracellularly, a portion of A&#946;42 enters the cytoplasm of the cell, possibly indicating a direct proteasome impairment mechanism. In support of A&#946;42 driving neurotoxicity by proteasome inhibition, genetically or pharmacologically increasing proteasome activity results in protection against cell death in mouse, fly, and cell culture A&#946; models of AD <ref type="bibr">[98]</ref>.</p><p>In addition to A&#946; aggregates, tau aggregates are another hallmark of AD that are neurotoxic and have been demonstrated to cause proteasome impairment (Table <ref type="table">1</ref>). Outside of the context of AD, tau is a protein involved in microtubule assembly <ref type="bibr">[99]</ref>. Hyperphosphorylation of tau disrupts its normal function and promotes tau fibril formation <ref type="bibr">[100]</ref><ref type="bibr">[101]</ref><ref type="bibr">[102]</ref>. Tau is normally a UPS substrate in healthy cells, and accumulation of tau results in a buildup of ubiquitinated tau, proteasome impairment, and proteasome interaction with tau, indicating that tau inhibits proteasomes directly <ref type="bibr">[103]</ref>. Pharmacological proteasome activation, using the FDA-approved drug cilostazol, reduces the accumulation of ubiquitinated tau <ref type="bibr">[104]</ref>. Explored further in section 2.2.1 Causes and Impacts of Ubiquitin Stress, A&#946; can also reduce free Ub, demonstrating the interconnectedness of proteasome and ubiquitin stress, and the ability of a single aggregated protein to have polytropic impacts on the UPS.</p><p>Parkinson's disease (PD) is a neurodegenerative disease where dopaminergic neurons of the substantia nigra decay and the disease is characterized by aggregated protein formations in the substantia nigra, known as Lewy Bodies. Lewy bodies contain &#593;-synuclein and Ub (Table <ref type="table">1</ref>) <ref type="bibr">[105]</ref>. Soluble &#593;-synuclein localizes to synapses, but its normal function in the cell is unclear and has been proposed to be involved in many processes, see the review by Bendor et. al. for a comprehensive review of proposed functions of &#945;-synuclein [106]. While most PD cases are sporadic with no clear genetic cause, many mutations in the UPS have been implicated in familial PD from genetic studies in humans, including in the deubiquitinase UCH-L1 and the E3 ligase, Parkin <ref type="bibr">[107,</ref><ref type="bibr">108]</ref>.</p><p>Impacting the proteasome, either with genetically or pharmacologically, can recapitulate PD in animal models. PSMC1 is a gene that encodes Rpt2, one of the ATPase subunits of the 19 S regulatory particle, and is critical in opening the gate of the core particle for substrate entry <ref type="bibr">[74,</ref><ref type="bibr">76]</ref>. In PSMC1 forebrain-specific and substantial nigra-specific conditional knockout (cKO) mouse models, neurons depleted for PSMC1 primarily contained 20 S proteasomes, which do not degrade ubiquitinated proteins <ref type="bibr">[109]</ref>. These mice developed neurodegeneration, as measured by a reduction in cortical thickness and neuronal cell death <ref type="bibr">[109]</ref>. The substantia nigra PSMC1 cKO mice showed massive neuronal loss and an accumulation of Ub in surviving neurons. The neurons depleted for PSMC1 also formed Lewy body-like inclusions <ref type="bibr">[109]</ref>. This study indicates that 26 S proteasome dysfunction can lead to a PD-like neurodegenerative disease, pointing to proteasome dysfunction as a potential precursor of neurodegeneration. In addition to a genetic model for PD caused by proteasome dysfunction, chemical models of PD have been established by injecting the proteasome inhibitor lactacystin into the forebrain of mice, rats, and minipigs <ref type="bibr">[110]</ref><ref type="bibr">[111]</ref><ref type="bibr">[112]</ref>. It was demonstrated more recently in these PSMC1 cKO mice that autophagy components become downregulated at the gene level upon long-term proteasome dysfunction, leading to a buildup of ubiquitinated mitochondrial proteins, ubiquitinated by <ref type="bibr">Parkin [113]</ref>. This study points to defective mitophagy and/or mitochondrial protein degradation as a potential driver of neurodegeneration in this proteasome-defective PD model (PSMC1 cKO), which is in line with autophagy defects observed in other PD models <ref type="bibr">[114]</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.1.2.">Mechanisms of proteasome impairment by aggregates-For the past ~30 years</head><p>, it has been understood that many disease-associated protein aggregates can bind proteasomes in vitro and impair proteasome function <ref type="bibr">[94,</ref><ref type="bibr">115,</ref><ref type="bibr">116]</ref>. However, the mechanism of impairment occurring and whether it varies from protein to protein was not well understood. The Smith Lab at West Virginia University has established that oligomeric aggregates of a range of protein misfolding disease-associated proteins all have a similar mechanism of proteasome impairment (Table <ref type="table">1</ref>) <ref type="bibr">[23]</ref>. The proteins tested were oligomers of &#945;-synuclein (associated with PD), A&#946; (associated with AD), and Huntingtin 53Q (Htt53Q: a mutant protein that causes Huntington's disease (HD). This research found oligomeric aggregates of intermediate size bind directly to the proteasome in vitro and allosterically inhibit proteasomal degradation by holding the proteasome gate in a closed conformation <ref type="bibr">[23]</ref>. In contrast, the large aggregates and small oligomers did not impact the ability of the proteasome to degrade a fluorescent proteasome substrate. Prior to this work, it was already demonstrated that small oligomers of A&#946; tend to be more cytotoxic than higher molecular weight aggregates, but the mechanism was unclear <ref type="bibr">[117]</ref>. Pairing these findings with the knowledge that proteasome activity is reduced with age in many cell types <ref type="bibr">[118,</ref><ref type="bibr">119]</ref>, the Smith Lab created the first transgenic animal model with an open-gate proteasome <ref type="bibr">[120]</ref>. Using C. elegans with a genetic perturbation to express a partially opengate proteasome, the lab determined these organisms had a longer lifespan and better ability to cope with oxidative and proteotoxic stress, although this came at the cost of a massive reduction in fertility compared with wildtype (WT) worms. Increased lifespan has also been demonstrated in C. elegans with overexpression of the 19 S proteasome subunit Rpn-6 and these worms have increased proteasome activity and resistance to proteotoxic stress <ref type="bibr">[121]</ref>. Similarly, protein aggregates form in aged yeast (S. cerevisiae) and can be reduced in a genetic background where proteasome components are upregulated <ref type="bibr">[122]</ref>.</p><p>While the above work implicates oligomeric aggregates as direct inhibitors of proteasomes, some aggregated protein structures may impair proteasomes in vivo. A recent study demonstrated that purified &#945;-synuclein can form different aggregated structures under different conditions <ref type="bibr">[123]</ref>. When these aggregates were injected into mouse brains and then examined by immunohistochemistry, only &#945;-synuclein fibrils that were arranged in a structure where the C-terminus was exposed became ubiquitinated, phosphorylated, and sequestered proteasomes in intracellular aggregates <ref type="bibr">[123]</ref>. All those characteristics are features of &#945;-synuclein fibrils in PD, indicating that the C-terminal exposed fibril conformation could be a driver of toxicity in vivo.</p><p>Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease characterized by the death of motor neurons and cytoplasmic aggregates containing ubiquitinated TAR DNAbinding protein 43 (TDP-43), an RNA processing protein (Table <ref type="table">1</ref>). Several causative mutations for ALS have been reported in proteins that promote proteasomal degradation, including the ATPase p97/VCP, which is required for the degradation of select UPS substrates <ref type="bibr">[124]</ref><ref type="bibr">[125]</ref><ref type="bibr">[126]</ref>. The most common causative mutation for familial ALS is a hexanucleotide expansion in the C9orf72 gene. One result of this mutation is the production of aggregated poly-glycine alanine (polyGA) C9orf72 peptides, which are toxic to neurons (Table <ref type="table">1</ref>) <ref type="bibr">[127]</ref>. Cryo-electron tomography of poly-GA peptides in neurons reveals the peptides form a twisted ribbon-like structure, in which proteasomes become stalled while attempting to degrade the aggregated peptides and become sequestered as a result of this stalling <ref type="bibr">[22]</ref>. In contrast to the mechanism identified for oligomeric aggregates, this is an example of a mechanism by which larger protein aggregates could directly impair proteasomes <ref type="bibr">[22,</ref><ref type="bibr">23]</ref>. Similarly, glycine-rich C-terminal fragments of TDP-43, known as TDP-25 itself can form aggregated inclusions, which cryo-electron tomography has revealed also physically sequester stalled proteasomes <ref type="bibr">[128]</ref>.</p><p>2.1.3. Cellular adaptations to proteasome stress-One of the major mediators of cellular adaptation to proteasome stress is the transcription factor Rpn4 in yeast and Nrf1 in mammals <ref type="bibr">[129,</ref><ref type="bibr">130]</ref>. Rpn4 and Nrf1 are both transcription factors that primarily upregulate proteasome component genes. The transcriptional program orchestrated by Rpn4 in yeast is called the proteasome stress response (PSR) <ref type="bibr">[131]</ref>, and Nrf1 activates a similar program in mammalian cells called the proteasome recovery pathway <ref type="bibr">[130]</ref>. Our group (the Neal lab at University of California, San Diego) and others have identified Rpn4 as a key mediator in adapting cells to misfolded membrane protein accumulation at the ER <ref type="bibr">[132,</ref><ref type="bibr">133]</ref>, as well as being crucial in adaptation to stressors that induce protein aggregation and certain forms of proteasome inhibition stress <ref type="bibr">[131]</ref>. Rpn4 is a cytoplasmic protein that is normally rapidly degraded by the proteasome, both in a ubiquitin-dependent and -independent manner <ref type="bibr">[134,</ref><ref type="bibr">135]</ref>. Upon proteasome stress, impairment of the proteasome naturally slows the degradation rate of Rpn4, causing an increase in Rpn4's stability and abundance <ref type="bibr">[129]</ref>. The increased pool of Rpn4 then accumulates in the nucleus, where it upregulates many proteasome components at the mRNA level, eventually leading to increased proteasome capacity <ref type="bibr">[129,</ref><ref type="bibr">136]</ref>. In contrast to the activation of Rpn4, Nrf1 is instead an ER-localized membrane protein that is proteolytically processed into an active transcription factor in response to proteasome impairment <ref type="bibr">[130,</ref><ref type="bibr">[137]</ref><ref type="bibr">[138]</ref><ref type="bibr">[139]</ref>.</p><p>As an example of the impact of Rpn4 in adaptation to stress, stabilizing Rpn4 in yeast by knockout (KO) of Ubr2, the E3 ligase that ubiquitinates Rpn4, results in increased replicative lifespan in yeast, and this effect is specific to the increase in proteasome capacity in these mutants <ref type="bibr">[140]</ref>. While in this example increasing proteasome capacity in aging cells is beneficial, there are examples in human diseases where the proteasome recovery pathway should be attenuated, such as in cancer. Proteasome inhibitors, such as bortezomib and carfilzomib, are frequently prescribed for the treatment of multiple myeloma and induce apoptosis of multiple myeloma cells <ref type="bibr">[141,</ref><ref type="bibr">142]</ref>. To determine if multiple myeloma cells depend on the proteasome recovery pathway, the Bianchi Lab at Brigham and Women's Hospital used multiple human myeloma cells lacking Ddi2, the protease that activates Nrf1, and found that these cells were less viable and more sensitive to proteasome inhibition <ref type="bibr">[143]</ref>. This provides a new strategy by which multiple myeloma cells that acquire proteasome inhibitor resistance can be targeted.</p><p>The PSMC3 gene encodes Rpt5, an ATPase subunit of the proteasome which also recognizes polyUb chains <ref type="bibr">[74]</ref>. There is a rare heterozygous monogenic human disease caused by a mutation in PSMC3 that results in impaired proteasome function <ref type="bibr">[144,</ref><ref type="bibr">145]</ref>. Patients with this mutation are deaf and blind, with neurological deficits. In patient-derived fibroblasts, there is a build-up of ubiquitinated proteins and an increase in the amount of 26 S proteasome. Despite increased levels of proteasomes, there was no increase in proteolytic capacity, indicating some fraction of the proteasome is non-functional <ref type="bibr">[144]</ref>. In the patientderived cells, the reduction in proteosome activity triggers constitutive activation of Nrf1. As a result, the Nrf1 pathway becomes exhausted and cannot be further activated by proteotoxic stress, which can be deleterious to the cells and is a potential cause of this developmental disorder <ref type="bibr">[144]</ref>. The role of Nrf1 in increasing UPS capacity in response to proteasome stress demonstrates the adaptability of cells to proteotoxic stress. Understanding the importance of this pathway for proper cellular function and cell survival could guide our understanding of rare diseases with defects in proteasome function.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.1.4.">Causes and impacts of ubiquitin stress-Ub</head><p>has wide-ranging roles in cellular functions and, as such, the amount of Ub must be well-regulated. Because of the process by which Ub is conjugated to proteins, the only Ub that is readily usable is monomeric, referred to as free Ub. The amount of free Ub in cells is known as the free Ub pool. When the free Ub pool is reduced to a level that disrupts ubiquitin-dependent processes, this state is ubiquitin stress <ref type="bibr">[59]</ref>.</p><p>When human cells in culture undergo heat shock, a form of stress that causes proteins to misfold, the cells accumulate ubiquitinated proteins and show a reduction in free Ub <ref type="bibr">[146]</ref>. When cells begin to recover from heat shock, they continue clearing soluble ubiquitinated proteins and increase the expression of Ub. In contrast, aggregated proteins that become ubiquitinated during heat stress are not cleared, posing a potential threat to cells in the aftermath of cellular stress <ref type="bibr">[146]</ref>.</p><p>Because of the many roles of Ub, depletion of free Ub can have wide-ranging cellular consequences, even outside of proteostasis. Both a mutant protein that causes HD (HttQ91) and a mutated, aggregation-prone luciferase can form IBs containing Ub <ref type="bibr">[147]</ref>. Because of the sequestration of Ub by these IBs, there is less monoubiquitination of histones, which is a signaling function of Ub that regulates the DNA damage response. As a result, the DNA damage response is impaired in the cells that have HttQ91 or luciferase IBs. This is an example of how ubiquitin stress, triggered by proteotoxic stress, can have downstream cellular effects outside of the proteostasis network.</p><p>In addition to the previously described characteristic of A&#946;42 to impair proteasomes, A&#946;42 applied extracellularly to primary neurons results in reduced free Ub. As a result, this causes a reduction in cell viability and an increase in the mRNA level of several inflammatory markers <ref type="bibr">[148]</ref>. This indicates ubiquitin stress may be one of the drivers of cytotoxicity by A&#946;42 aggregates, in addition to causing proteasome stress.</p><p>Ub is commonly found in protein aggregates and ubiquitinated aggregates are a hallmark of protein misfolding diseases <ref type="bibr">[149]</ref>. Two types of ubiquitinated intracellular protein inclusions are the juxtanuclear quality control compartment (JUNQ) and insoluble protein deposit (IPOD) <ref type="bibr">[150]</ref>. JUNQ inclusions are hubs of proteasomal degradation, whereas IPOD inclusions generally contain terminally aggregated ubiquitinated proteins <ref type="bibr">[150]</ref>. The Yerbury group at Illawarra Health and Medical Research Institute has extensively studied the impact of aggregation-prone proteins associated with ALS on Ub dynamics <ref type="bibr">[151,</ref><ref type="bibr">152]</ref>. The lab initially characterized the types of aggregates formed by mutants of three proteins implicated in ALS (Table <ref type="table">1</ref>). The proteins interrogated in this study were superoxide dismutase 1 (SOD1), an enzyme with antioxidant functions, TDP-43, an RNA-processing protein, and Fused in Sarcoma (FUS), an RNA-binding protein <ref type="bibr">[153,</ref><ref type="bibr">154]</ref>. SOD1 forms JUNQ inclusions while TDP-43 and FUS can form JUNQ or IPOD-like inclusions, indicating the exact type of protein inclusion formed is not common to all cases of ALS <ref type="bibr">[155]</ref>. The group's research has determined, in NSC-34 cells (mouse motor neuron-like immortalized cells), that disease-associated mutants of SOD1, TDP-43, and FUS all form aggregates that include Ub conjugates with K48 and K63 linkages. The aggregated forms of mutant SOD1 and FUS result in reduced UPS activity and a reduction in free Ub, in a manner that does not occur with the WT form of each protein or because of the non-aggregated mutant protein. In contrast, aggregated WT and mutant TDP-43 both reduce UPS activity when overexpressed, but only aggregated mutant TDP-43 specifically results in decreased free Ub <ref type="bibr">[155]</ref>.</p><p>2.1.5. Friends of ubiquitin: ubiquitin-like proteins in stress-While ubiquitination is the most common post-translational modification to target proteins for degradation, mammalian cells also encode a collection of ubiquitin-like proteins (UBLs) that can also target proteins for proteasomal degradation. One UBL, SUMO, plays a role in modulating stress granule dynamics <ref type="bibr">[156]</ref>. Stress granules are cytoplasmic amorphous aggregates of RNA and protein that form under conditions of cellular stress, as an adaptive response to sequester cytotoxic oligomeric aggregates <ref type="bibr">[157]</ref>. SUMOlyation can act as a primer for ubiquitination, which is carried out by the SUMO-targeted ubiquitin ligase (StUbL) pathway. Under stress conditions, RNA binding proteins, which are commonly included in stress granules, in the nucleus become SUMOlyated and are then recognized by the Ub E3 ligase Rnf4, a component of the StUbL pathway. These now ubiquitinated proteins targeted by the StUbL pathway are then degraded by the nuclear proteasome. If the StUbL pathway is impaired, stress granules will still form, but their disassembly is slowed <ref type="bibr">[156]</ref>. Another recent study investigating the ubiquitome under various stress conditions found that ubiquitination of proteins in stress granules was required for stress granule disassembly, but only when the stress granules were induced by heat shock and not by arsenite <ref type="bibr">[158]</ref>. In contrast to the work on StUbL on stress granules, this study demonstrated that ubiquitination was important because it allowed for recruitment of the ATPase p97/VCP to disassemble stress granules <ref type="bibr">[158]</ref>.</p><p>Another UBL, NEDD8, has been shown in human cell culture to serve an adaptive role under conditions of cellular stress, by promoting cytoprotective protein aggregation and sparing UPS function as a result <ref type="bibr">[159]</ref> . Specifically, when cells are heat shocked, the ribosomal protein RPL7 becomes both NEDDylated and ubiquitinated, resulting in a poor proteasome substrate compared to ubiquitination alone. Thus, the mixed Ub/NEDD8 chains are less efficient than ubiquitination chains alone. This slowing of RPL7 degradation results in nuclear stress granules but prevents nuclear proteasome function from becoming overwhelmed <ref type="bibr">[159]</ref>.</p><p>2.1.6. Deubiquitinases in mediating ubiquitin stress-DUBs are proteases that specifically cleave the isopeptide bonds formed by Ub, and act on specific linkage types or chain lengths, including releasing Ub chains from ubiquitinated proteins or breaking down Ub chains into Ub monomers <ref type="bibr">[53,</ref><ref type="bibr">54]</ref>. Several DUBs regulate the pool of free Ub by recycling Ub on proteins degraded by the proteasome <ref type="bibr">[160]</ref>. This includes one of the DUBs that interacts with the proteasome lid, Usp14 in mammals and Ubp6 in yeast <ref type="bibr">[59,</ref><ref type="bibr">88,</ref><ref type="bibr">161]</ref>.</p><p>Ubp6 is important for cell survival in circumstances where proteotoxicity disrupts free Ub. Prions are a type of misfolded proteins that are highly toxic and induce misfolding and aggregation of properly folded proteins <ref type="bibr">[123,</ref><ref type="bibr">162]</ref>. Yeast Ubp6 KO cells expressing prions exhibit cellular stress, as measured by a reduction in growth compared to <ref type="bibr">WT yeast [88]</ref>. This growth stress seems to be related to the inability of Ubp6 KO cells to efficiently recycle Ub, as increasing the amount of monomeric Ub in Upb6 KO cells with prions restores growth. Ubp6 is important for ubiquitin recycling, because this DUB releases Ub from UPS-targeted proteins before proteasomal degradation, rather than allowing Ub to be degraded along with the targeted protein <ref type="bibr">[84]</ref>. Proteasomal degradation of Ub as a driver for Ub depletion in these Ubp6 KO cells is also supported by the observation that Ub was stabilized when the proteasome was inhibited in these cells <ref type="bibr">[88]</ref>. The absence of Ubp6 also increases the sensitivity of cells to treatment with amino acid analogs that cause disruptions to proteostasis <ref type="bibr">[88]</ref>. Our lab has also observed growth stress in Ubp6 KO yeast expressing a misfolded membrane protein, as well as in cells lacking other DUBs, indicating a broad role for DUBs in maintaining Ub homeostasis and in adapting yeast cells to proteotoxic stress <ref type="bibr">[132]</ref>.</p><p>A mouse with a loss of function mutation in the Ubp6 homolog, Usp14, displays neurodegeneration and ataxia. This mutation, an insertion in intron 5 of Usp14, causes a large reduction in the expression of Usp14 and the mice have reduced neurotransmitter release and low synaptic transmission <ref type="bibr">[163]</ref>. Initially puzzling, the neurons of these mice do not have ubiquitin-containing protein aggregates <ref type="bibr">[163]</ref>. This mutation causes polyUb chains to be degraded rather than recycled, which in turn lowers the amount of free Ub in neurons without causing direct impairment to proteasomes <ref type="bibr">[161]</ref>. The decreased amount of free Ub is the primary reason for this neurological dysfunction, demonstrating that ubiquitin stress can be a driver of cellular dysfunction in the absence of protein aggregation <ref type="bibr">[161]</ref>. In these mice, neurological dysfunction by ubiquitin stress can be relieved through the influx of free Ub and restored expression of Usp14. Restoring Usp14 and increasing expression of monomeric Ub in ataxic mice restores synaptic function, motor function, and muscle mass to WT levels <ref type="bibr">[164]</ref><ref type="bibr">[165]</ref><ref type="bibr">[166]</ref><ref type="bibr">[167]</ref>. The benefits of increasing free Ub in ataxic mice may have a narrow therapeutic window, as too much Ub results in additional neurological dysfunction, decreasing muscle mass, and impairing motor nerve function <ref type="bibr">[168]</ref>.</p><p>Injecting mice with a Usp14 inhibitor results in the inhibition of long-term memory, as measured through fear response behavioral tests <ref type="bibr">[169]</ref>. In Usp14-deficient ataxic mice, presynaptic transmission and signaling from the hippocampus to the amygdala are impaired, although this effect appears to be caused by a protease-independent function of Usp14 <ref type="bibr">[170,</ref><ref type="bibr">171]</ref>. This decrease in presynaptic transmission with a Usp14 genetic mutant potentially explains the long-term memory deficits in mice treated with a Usp14 inhibitor.</p><p>Usp14 itself acts as a regulator of proteasome activity, with overexpression of Usp14 inhibiting proteasome function <ref type="bibr">[172]</ref>. The E3 ligase Trim11 can bind to Usp14, thereby preventing the interaction between Usp14 and the proteasome. This interaction increases proteasome activity, including the ability of the proteasome to degrade aggregated proteins. This increase in proteasome activity can be adaptive for cancer cells, as Trim11KO in a xenograft cancer mouse model reduces tumor growth significantly and overexpression of Trim11 in the same model has the inverse effect <ref type="bibr">[172]</ref>.</p><p>Two DUBs have been implicated in stress granule dynamics; Usp5 and Usp13 <ref type="bibr">[173]</ref>. The Komada Lab at the Tokyo Institute of Technology used HeLa cells, fluorescence, and super-resolution microscopy to determine that K48-and K63-linked Ub chains co-localize in stress granules formed by heat stress. Stress granule dynamics are regulated by these Ub chains, and the chains are regulated by stress granule-associated Usp5 and Usp13. Usp5KO or Usp13KO results in faster assembly and slower disassembly of stress granules, meaning these DUBs antagonize the formation of stress granules. However, the role of polyUb chains in stress granule dynamics is disputed. Work from Eric Bennett's lab at University of California, San Diego has demonstrated that inhibiting ubiquitination does not impact stress granule dynamics, and the majority of Ub in stress granules is actually monomeric <ref type="bibr">Ub [174]</ref>. This demonstrates a circumstance where monomeric Ub is not necessarily reduced in cells, but rather free Ub is physically sequestered and could result in ubiquitin stress.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.">The endoplasmic reticulum and the ubiquitin proteasome system</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.1.">Protein quality control at the ER and proteotoxic stress responses</head><p>The endoplasmic reticulum (ER) is a major site of protein synthesis and protein folding, specifically for secreted proteins and membrane proteins. The UPS pathway utilized specifically at the ER is called ER-associated degradation (ERAD) <ref type="bibr">[9,</ref><ref type="bibr">175]</ref>. The ER is a well-studied site of PQC by the UPS and it is well-understood how proteotoxic stress is handled at the ER <ref type="bibr">[176]</ref>. The canonical ER stress response to misfolded protein accumulation is the unfolded protein response (UPR). The UPR is the best-studied cellular adaptation pathway for proteotoxic stress. This section of the review will explore the interplay between the UPR and ERAD function (Fig. <ref type="figure">4</ref>).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.1.1.">Endoplasmic reticulum associated degradation and ubiquitin</head><p>proteasome system impairment-Compared to cytoplasmic protein quality control by the UPS, there are additional challenges to UPS degradation of ER-localized proteins. The ER is responsible for folding secreted proteins destined for the plasma membrane and secretory pathway resident proteins <ref type="bibr">[177]</ref>. When ER proteins are degraded by ERAD, they must be moved across the ER membrane for degradation by the cytoplasmic proteasome, a process termed retrotranslocation <ref type="bibr">[178,</ref><ref type="bibr">179]</ref>. A universal feature of ERAD in both yeast and mammalian cells is the use of an ATPase, p97/VCP in mammals and Cdc48 in yeast, to provide the energy for retrotranslocation and to mechanically assist with protein unfolding before proteasomal degradation <ref type="bibr">[180]</ref><ref type="bibr">[181]</ref><ref type="bibr">[182]</ref>.</p><p>Several neurodegenerative diseases, most famously HD, are caused by abnormally long stretches of polyglutamine in specific proteins (known as polyQ expansions). When expressed in yeast and in neuronal-like PC12 cells (derived from rats), a polyQ expanded Huntingtin protein (103Q Htt exon 1) quickly impairs ERAD (6 h in yeast and 8 h in PC12 cells), prior to the onset of global UPS impairment. This impairment of ERAD by polyQ aggregates is toxic and driven by the sequestration of critical ERAD components (Table <ref type="table">1</ref>). For example, p97 and Cdc48 are sequestered by these aggregates in PC12 cells and yeast cells, respectively <ref type="bibr">[183]</ref>. Overexpressing the sequestered ERAD components promotes cell survival <ref type="bibr">[183]</ref>. Additional evidence that UPS is impaired in HD comes from the observation that K48 Ub linkages accumulate globally with the expression of a GFP-tagged polyQ Htt variant (HttQ150GFP) in a mouse neuroblastoma cell line <ref type="bibr">[184]</ref>. However, in a HD mouse model, UPS function is not impaired globally in the brain <ref type="bibr">[185]</ref>. While there are changes in protein ubiquitination in these mice, these changes are not the same as in mice injected with a proteasome inhibitor <ref type="bibr">[186]</ref>. One proposed explanation for this discrepancy is that ubiquitination may be impacted in specific neuronal cell types that contribute to HD, rather than globally. Impairment of ERAD, particularly by polyQ expanded proteins, can be caused independently of impairment to the UPS as a whole and can be a driver of toxicity.</p><p>3.1.2. Rhomboid proteins: the bridge between ERAD and proteotoxic stress -A major class of proteins that participate in ERAD is the rhomboid protein family. Rhomboid proteins are intramembrane proteins with two subclasses: rhomboid proteases and rhomboid pseudoproteases, with the pseudoproteases lacking a proteolytic active site. In both yeast and mammalian cells, ER-localized rhomboid proteins have a role in the retrotranslocation step of ERAD <ref type="bibr">[179,</ref><ref type="bibr">[187]</ref><ref type="bibr">[188]</ref><ref type="bibr">[189]</ref>. The mammalian rhomboid protease RHBDL4 can cleave aggregation-prone proteins and direct the fragments to degradation by the proteasome <ref type="bibr">[190]</ref>. The Neal Lab has recently established the ability of rhomboid pseudoproteases to similarly act on aggregation-prone membrane proteins, with yeast rhomboid pseudoprotease Dfm1 preventing misfolded membrane protein aggregation <ref type="bibr">[132]</ref>. When membrane proteins aggregate in the absence of Dfm1, it is toxic to the cells. This toxicity appears to be primarily driven by ubiquitin stress, as the free Ub pool is reduced by roughly half and the cells grow normally when Ub expression is increased <ref type="bibr">[132]</ref>. Remarkably, in cells lacking Dfm1, expressing the mammalian homologs of Dfm1, Derlin-1 or Derlin-2, restores the ability of yeast cells to prevent membrane protein aggregation and prevents ubiquitin stress <ref type="bibr">[132]</ref>.</p><p>Several mammalian rhomboid proteins that participate in ERAD are also involved in stress alleviation. Derlin-1 is expressed in 66% of breast cancer tumors, but it is not expressed in healthy mammary cells <ref type="bibr">[191]</ref>. This rhomboid protein is also upregulated by ER stress in normal cells and appears to play a protective role against apoptosis in breast cancer <ref type="bibr">[191]</ref>. Protection against apoptosis by ERAD is generally accepted due to the ability of this degradation pathway to ameliorate proteotoxic threats to the cell and promote cellular health. Derlin-1 is also implicated in ALS through its interaction with mutant SOD1. This interaction causes an impairment to ERAD that results in ER stress and leads to motor neuron death <ref type="bibr">[192]</ref>. Overexpression of Derlin-1 promotes clearance of SOD1, through both proteasomal degradation and autophagy, as well as reduces ER stress and apoptosis <ref type="bibr">[193]</ref>. In cardiomyocytes, Derlin-3 is upregulated several-fold in response to ER stress, and its upregulation enhances ERAD and prevents apoptosis <ref type="bibr">[194]</ref>. Additionally, ERAD appears to be critical in adapting cardiomyocytes to ER stress, as knockdown of the ER-localized E3 ligase Hrd1 increases apoptosis when ER stress is chemically induced in these cells <ref type="bibr">[195]</ref>. The rhomboid protease RHBDL4 also plays a protective role against ER stress, as RHBDL4 KO mice are more sensitive to ER stress-inducing drugs than WT mice, and develop liver steatosis, a disease that can be induced by chronic ER stress <ref type="bibr">[196]</ref>.</p><p>3.1.3. The unfolded protein response and the ubiquitin proteasome system -The UPR is a well-investigated response pathway to proteotoxic stress at the ER. The pathway can be activated by the accumulation of misfolded soluble ER proteins. The UPR in mammalian cells utilizes three ER membrane-localized sensors for activation; Ire1, <ref type="bibr">PERK,</ref>. All three sensors, through different mechanisms, result in downstream activation of gene networks that seek to restore proteostasis (for a thorough review of the UPR, please refer to <ref type="bibr">Hetz,</ref><ref type="bibr">C.,</ref><ref type="bibr">et al.) [203]</ref>.</p><p>The UPR is a powerful pathway for adapting cells to stressors when activated transiently, however, constitutive activation can cause additional stress and cellular dysfunction, leading to apoptosis in mammalian cells <ref type="bibr">[204]</ref>. Treatment of multiple myeloma cells with a proteasome inhibitor is an example of how apoptosis because of UPR activation can be leveraged for disease treatment. Treating these cells with a proteasome inhibitor causes an accumulation of misfolded ER proteins and leads to a maladaptive UPR response which triggers apoptosis <ref type="bibr">[205]</ref>.</p><p>Because ERAD specifically degrades misfolded proteins at the ER, it is closely intertwined with the UPR. In fact, the UPR causes upregulation of many ERAD components in mammalian cells, including Derlin-2, Derlin-3, and Hrd1, and allows for ERAD to more effectively degrade proteins <ref type="bibr">[194,</ref><ref type="bibr">[206]</ref><ref type="bibr">[207]</ref><ref type="bibr">[208]</ref>. Additionally, some mammalian ER E3 ligases can be stabilized by ER stress prior to the upregulation of ERAD components in order to quickly increase ERAD capacity. This is caused by autoubiquitination and degradation of the E3 ligase gp78, with degradation of other ER E3 ligases being slowed as a result of reduced ubiquitination from gp78 <ref type="bibr">[209]</ref>.</p><p>It has been appreciated for nearly two decades that ER stress can result in impairment of the UPS <ref type="bibr">[210]</ref>. In yeast without Hac1, the transcription factor activated by Ire1, the rate of degradation of a misfolded protein at the ER is reduced <ref type="bibr">[211]</ref>. However, the degradation of a misfolded cytosolic protein is not impacted, indicating unresolved ER stress impacts ERAD, but not the UPS as a whole <ref type="bibr">[211]</ref>.</p><p>Neuroinflammation is a potential driver of both aging and neurodegenerative diseases. Using lipopolysaccharide (LPS) injection in the hippocampus of rats as a model of neuroinflammation, the Ruano group at Universidad de Sevilla found that the Ire1 and Atf6 branch of the UPR are acutely activated by neuroinflammation, but attenuated by ~12 h post injection <ref type="bibr">[212]</ref>. As a result of this attenuation, ERAD components become downregulated, resulting in defective ER quality control. It will be important in future studies to understand how PQC defects as a result of neuroinflammation affect cellular health and survival.</p><p>Aggregation of human islet amyloid polypeptide (hIAPP) from pancreatic &#946;-cells is another illustrative example of how proteotoxicity, the UPR, and the UPS are connected in disease pathogenesis. hIAPP deposits occur extracellularly and are characteristic of Type 2 diabetes in. However, the deposition of hIAPP outside the cell triggers the UPR, both in a cell culture and mouse model of Type 2 diabetes <ref type="bibr">[213,</ref><ref type="bibr">214]</ref>. In addition to UPR activation, cells also show UPS impairment, as evidenced by a buildup of ubiquitinated proteins, and this dysfunction appears to be due to prolonged ER stress in pancreatic &#946;-cells <ref type="bibr">[214]</ref>.</p><p>Increasing proteasome activity increases cell viability in the presence of hIAPP <ref type="bibr">[214]</ref>. Exogenous hIAPP expression in mice reduces the expression of UCH-L1, a DUB required for proteasomal degradation, at the protein and mRNA level. This downregulation of UCH-L1 promotes apoptosis due to UPS impairment <ref type="bibr">[215]</ref>. It is unclear whether ER stress directly causes the downregulation of UCH-L1, or whether UCH-L1 downregulation is caused by another mechanism resulting in the promotion of ER stress through UPS dysfunction <ref type="bibr">[215]</ref>. The proteasome itself is also able to degrade hIAPP, meaning that proteasome impairment could lead to an increase in hIAPP accumulation. However, through a negative feedback loop, proteasome impairment decreases the transcription and secretion of hIAPP in pancreatic &#946;-cells [216].</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.">Conclusions and perspectives</head><p>The ubiquitin proteasome system (UPS) is one of the major protein quality control pathways in eukaryotic cells and is critical for preventing and adapting to proteotoxic stress. Proteotoxic stress and the UPS are closely interconnected, as proteotoxic stress impairs the UPS and UPS dysfunction leads to proteotoxic stress (Fig. <ref type="figure">3</ref>). Cells are finely tuned to prevent proteotoxic stress, but proteotoxic stress can easily overwhelm the UPS and lead to proteostasis failure.</p><p>Modulating the UPS to adapt cells to proteotoxic stress is a promising strategy for potential therapeutics. While proteasome inhibitors are currently approved for some cancers to induce apoptosis <ref type="bibr">[141,</ref><ref type="bibr">142]</ref>, increasing UPS capacity could also be harnessed to enhance cell survival in diseased cells, such as in neurodegenerative diseases. There are two potential strategies for increasing UPS capacity: 1) increasing proteasome activity and 2) increasing the pool of free ubiquitin <ref type="bibr">[120,</ref><ref type="bibr">132,</ref><ref type="bibr">140,</ref><ref type="bibr">164]</ref>. In addition, cells use several pathways to adapt to proteotoxic stressors and modulate UPS capacity, the main pathways being the unfolded protein response, the proteasome recovery pathway (in mammals), and the proteasome stress response (in yeast) <ref type="bibr">[130,</ref><ref type="bibr">131,</ref><ref type="bibr">176]</ref>. Modulation of these pathways will be a valuable strategy for treating a myriad of protein misfolding diseases.</p><p>Neurodegenerative diseases are examples of well-studied protein misfolding diseases in which the UPS is frequently impaired. While large amyloids or insoluble protein deposits are characteristics of several neurodegenerative diseases, smaller oligomeric aggregates are usually the drivers of cytotoxicity <ref type="bibr">[23]</ref><ref type="bibr">[24]</ref><ref type="bibr">[25]</ref><ref type="bibr">[26]</ref>. For several disease-causing proteins, oligomers have been shown to impair proteasome function and bind directly to proteasomes in in vitro experiments <ref type="bibr">[23]</ref>. It will be an important line of inquiry to understand how UPS dynamics are affected during the early stages of neurodegenerative diseases in animal models. Ub is initially conjugated to an E1 ubiquitin activating enzyme, in an ATP-dependent reaction, and is then transferred to an E2 Ub conjugation enzyme. E3 ligases bring an Ub-E2 complex in proximity with a target protein, to which Ub gets transferred. Additional ubiquitins are conjugated through the same processes to create a polyUb chain. This chain targets proteins to the 26 S proteasome, where deubiquitinases (DUBs) remove Ub before ATP-dependent proteasomal degradation. Other DUBs specifically break down Ub chains to replenish the cellular pool of free ubiquitin, which is then accessible for E1 enzymes. Created with BioRender.com.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Fig. 2. Misfolded Protein Structures</head><p>Graphical depiction of an unfolded protein, native conformation protein, and several misfolded protein structures that are referenced throughout this review. Created with BioRender.com.  The left panel of the figure depicts the role of ERAD under normal physiological conditions. Misfolded proteins are retrotranslocated from the ER lumen into the cytoplasm, in a ubiquitin-dependent process that requires a retro-translocon and the ATPase p97/VCP in mammalian cells and Cdc48 in yeast cells. The right panel depicts that proteotoxic stress from protein aggregates can lead to impairment of ERAD. This impairment increases proteotoxic stress specifically at the ER and leads to activation of the UPR, a pathway that aims to restore ER proteostasis. Created with BioRender.com. </p></div><note xmlns="http://www.tei-c.org/ns/1.0" place="foot" xml:id="foot_0"><p>Semin Cell Dev Biol. Author manuscript; available in PMC 2024 March 15.</p></note>
		</body>
		</text>
</TEI>
